Showing 1 - 3 results of 3 for search 'Estefanía Paula Juliá', query time: 0.03s Refine Results
  1. 1
    Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer

    Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer by Estefanía Paula Juliá, José Mordoh, Estrella Mariel Levy

    Published 2020-06-01
    Get full text
    Article
  2. 2
    Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

    Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells by Estefanía Paula Juliá, Analía Amante, María Betina Pampena, José Mordoh, José Mordoh, José Mordoh, Estrella Mariel Levy

    Published 2018-09-01
    Get full text
    Article
  3. 3
    Phenotypic and functional dysregulated blood NK cells in Colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15.

    Phenotypic and functional dysregulated blood NK cells in Colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15. by Yamila Sol Rocca, María Paula Roberti, Estefanía Paula Juliá, María Betina Pampena, Luisina Bruno, Sergio Rivero, Eduardo Huertas, Fernando Sánchez Loria, Alejandro Pairola, Anne Caignard, José Mordoh, José Mordoh, José Mordoh, Estrella Mariel Levy

    Published 2016-10-01
    Get full text
    Article

Search Tools: